Amishi Y. Shah - Concepedia

Author

Amishi Y. Shah

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A. Shah, A.Y. Shah, Adit SHAH, Amishi Y. Shah, Amishi Shah, Amishi Y Shah, Amishi Y. Shah, Amishi Y. Shah, MD, Amishi Yogesh Shah, Amishi Yogesh Shah, MD

274

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute National Cancer Institute National Institutes of Health

About

Amishi Y. Shah is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	30	1.7K
2	Health Sciences	8	8	234
3	Applied Physiology	1	1	28
4	Diagnostic Sciences	1	1	21
5	Exercise Physiology	1	1	28

Amishi Y. Shah

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Toni K. Choueiri, Thomas Powles, Mauricio Burotto, New England Journal of Medicine	2021	1.6K
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma Jianjun Gao, Neema Navai, Omar Alhalabi, Nature Medicine Surgical OncologyUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2020	300
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Robert J. Motzer, Thomas Powles, Mauricio Burotto, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyCabozantinib Versus Sunitinib	2022	286
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study Chung‐Han Lee, Amishi Y. Shah, Drew Rasco, The Lancet Oncology UrologyGenitourinary CancerStudy 111/Keynote-146MedicinePhase 1B/2	2021	178
Distinct Roles for the p110α and hVPS34 Phosphatidylinositol 3′-Kinases in Vesicular Trafficking, Regulation of the Actin Cytoskeleton, and Mitogenesis Uma Siddhanta, James McIlroy, Amishi Y. Shah, The Journal of Cell Biology	1998	149
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke, European Journal of Cancer UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer Treatment	2019	120
696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Annals of Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2020	116
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study Fangwen Zou, David M. Faleck, Anusha Shirwaikar Thomas, Journal for ImmunoTherapy of Cancer	2021	111
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies Bradley A. McGregor, Matthew T. Campbell, Wanling Xie, Cancer	2020	109
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy Sang T. Kim, Yanshuo Chu, Mercy Misoi, Nature Communications	2022	103

Page 1